A pair of freshmen Ohio State fencers have spent the last few weeks preparing for their first Junior Olympic competition, which could pave their way to the United States World Championship team.Oliver Shindler and Ally Micek will take part in the four-day competition set to be held Friday through Monday at the Cleveland Convention Center.Shindler said he and Micek have been competing this entire season to accumulate enough points to qualify for the Junior Olympics. The pair have been getting advice and encouragement from many of the older members of the team.Micek said three men and three women will be selected from the Junior Olympics to represent the United States, making this a huge opportunity to be recognized on the national and international level.This isn’t Shindler’s and Micek’s first time competing on such a grand stage, however. After meeting each other through fencing in high school, the two traveled internationally on the same team, competing and representing the U.S.“When I first started, I was just doing this for fun, but once I got into high school, I realized the opportunities,” Micek said. “Once you get into high school, it was like a dream for me to compete in college.”The pair are both epee fencers, meaning their event uses the largest and heaviest weapons of the three main events (the other two being foil and sabre). Points are scored by making contact with the point of the weapon on any spot of the opponent’s body.Shindler said many of the upperclassmen on the team have been in their position before when they were freshmen, so they are a great resource for the young guns to turn to when they have questions about preparing.“A lot of the top guys like (OSU sophomores) Marc-Antoine (Blais Belanger) and Lewis Weiss, they’ve just been helping me mentally prepare for all of the competitions this season, whether they be college or national,” Shindler said.The duo is getting help and advice from other teammates on the team in order to better prepare.“Same thing goes for the upperclassmen girls, we talk about it and they’ve all been in the same situation as we were, like, two years ago. They have really solid advice for us,” Micek said.Despite the grand implications, Shindler said he is looking to prepare for this weekend’s Junior Olympics event just like any other competition.“I prepare the same for every competition,” he said.
Nivolumab is currently available through the NHS Cancer Drugs Fund for both previously treated squamous non-small-cell lung cancer and for previously treated non-squamous non-small-cell lung cancer.There are around 47,200 new lung cancer cases in the UK every year, and it is the UK’s third most common cancer. Want the best of The Telegraph direct to your email and WhatsApp? Sign up to our free twice-daily Front Page newsletter and new audio briefings. Research on 854 patients, presented by Dr Scott Gettinger of Yale Comprehensive Cancer Centre in the US, showed that those on the drug were five times more likely to still be alive after five years than those on conventional chemotherapy (docetaxel).Five-year survival rates were 13.4 per cent for people on the drug compared to 2.6 per cent for those on chemotherapy. And eight per cent of those given immunotherapy had not seen the disease progress – compared with none of those on conventional treatment. A new immunotherapy cancer drug boosts survival rate five-fold, scientists from Yale have found. Patients with advanced lung cancer were far more likely to be alive after five years, compared with those given standard chemotherapy.The immunotherapy drug nivolumab, which is used for several cancers, works by blocking a protein that stops the immune system attacking cancer cells.The drug helps the patient’s own immune system find and destroy cancer cells as they spread.New research presented at the World Conference on Lung Cancer in Barcelona shows the drug can have a powerful effect in extending survival for people with advanced lung cancer who have few treatment options.It is the first time clinical data has been presented showing how patients are faring after five years on the medicine.